首页 > 最新文献

Cleveland Clinic Journal of Medicine最新文献

英文 中文
Dealing with the "T" (testosterone). 与 "T"(睾酮)打交道。
IF 6.1 4区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-02-02 DOI: 10.3949/ccjm.91b.02024
Brian F Mandell
{"title":"Dealing with the \"T\" (testosterone).","authors":"Brian F Mandell","doi":"10.3949/ccjm.91b.02024","DOIUrl":"10.3949/ccjm.91b.02024","url":null,"abstract":"","PeriodicalId":10245,"journal":{"name":"Cleveland Clinic Journal of Medicine","volume":"91 2","pages":"78-79"},"PeriodicalIF":6.1,"publicationDate":"2024-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139671389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Our Peer-Reviewers for 2023. 我们 2023 年的同行评审员
IF 6.1 4区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-02-02
{"title":"Our Peer-Reviewers for 2023.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":10245,"journal":{"name":"Cleveland Clinic Journal of Medicine","volume":"91 2","pages":"85"},"PeriodicalIF":6.1,"publicationDate":"2024-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139671394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Should I start an SGLT-2 inhibitor in my patient with heart failure and chronic kidney disease? 对于患有心力衰竭和慢性肾病的患者,是否应该开始使用 SGLT-2 抑制剂?
IF 6.1 4区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-02-02 DOI: 10.3949/ccjm.91c.02001
Taher Modarressi
{"title":"Should I start an SGLT-2 inhibitor in my patient with heart failure and chronic kidney disease?","authors":"Taher Modarressi","doi":"10.3949/ccjm.91c.02001","DOIUrl":"10.3949/ccjm.91c.02001","url":null,"abstract":"","PeriodicalId":10245,"journal":{"name":"Cleveland Clinic Journal of Medicine","volume":"91 2","pages":"82"},"PeriodicalIF":6.1,"publicationDate":"2024-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139671395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
von Willebrand disease: A guide for the internist. 冯-威廉氏病:内科医生指南
IF 6.1 4区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-02-02 DOI: 10.3949/ccjm.91a.22033
Varinder Kaur, Omar Elghawy, Saarang Deshpande, David Riley
von Willebrand disease (VWD), the most common inherited bleeding disorder, results when patients either do not make enough von Willebrand factor (VWF) or make defective VWF. The pathophysiology of this disorder is complex but needs to be understood to interpret the diagnostic tests. Most patients have mild to moderate symptoms and can be adequately counseled and managed by a general internist, but some need to consult a hematologist. We review the pathophysiology of VWD, its subtypes, common presentations of each subtype, diagnostic testing, and management of mild as well as severe clinical manifestations of VWD.
冯-威廉氏病(VWD)是最常见的遗传性出血性疾病,是由于患者体内的冯-威廉因子(VWF)不足或有缺陷而导致的。这种疾病的病理生理学非常复杂,但需要通过了解病理生理学来解释诊断测试。大多数患者的症状为轻度至中度,可由普通内科医生给予适当的指导和处理,但有些患者需要咨询血液科医生。我们回顾了 VWD 的病理生理学、其亚型、各亚型的常见表现、诊断测试以及轻度和重度 VWD 临床表现的处理。
{"title":"von Willebrand disease: A guide for the internist.","authors":"Varinder Kaur, Omar Elghawy, Saarang Deshpande, David Riley","doi":"10.3949/ccjm.91a.22033","DOIUrl":"https://doi.org/10.3949/ccjm.91a.22033","url":null,"abstract":"von Willebrand disease (VWD), the most common inherited bleeding disorder, results when patients either do not make enough von Willebrand factor (VWF) or make defective VWF. The pathophysiology of this disorder is complex but needs to be understood to interpret the diagnostic tests. Most patients have mild to moderate symptoms and can be adequately counseled and managed by a general internist, but some need to consult a hematologist. We review the pathophysiology of VWD, its subtypes, common presentations of each subtype, diagnostic testing, and management of mild as well as severe clinical manifestations of VWD.","PeriodicalId":10245,"journal":{"name":"Cleveland Clinic Journal of Medicine","volume":"31 1","pages":""},"PeriodicalIF":6.1,"publicationDate":"2024-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139665353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In Reply: Should I start an SGLT-2 inhibitor in my patient with heart failure and chronic kidney disease? 回复我是否应该为心力衰竭和慢性肾病患者开始使用 SGLT-2 抑制剂?
IF 6.1 4区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-02-02 DOI: 10.3949/ccjm.91c.02002
Pooja Prasad, Megha Prasad
{"title":"In Reply: Should I start an SGLT-2 inhibitor in my patient with heart failure and chronic kidney disease?","authors":"Pooja Prasad, Megha Prasad","doi":"10.3949/ccjm.91c.02002","DOIUrl":"10.3949/ccjm.91c.02002","url":null,"abstract":"","PeriodicalId":10245,"journal":{"name":"Cleveland Clinic Journal of Medicine","volume":"91 2","pages":"82-83"},"PeriodicalIF":6.1,"publicationDate":"2024-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139671392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure? 急性失代偿性心力衰竭患者何时应考虑使用 SGLT-2 抑制剂?
IF 6.1 4区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-02-02
{"title":"When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":10245,"journal":{"name":"Cleveland Clinic Journal of Medicine","volume":"91 2","pages":"118"},"PeriodicalIF":6.1,"publicationDate":"2024-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139671398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What are the management considerations for venous thromboembolic events in patients with cirrhosis? 肝硬化患者静脉血栓栓塞事件的处理注意事项有哪些?
IF 6.1 4区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-02-02 DOI: 10.3949/ccjm.91a.23045
Marie M Plante, Emily B Wolf, Razvan M Chirila
{"title":"What are the management considerations for venous thromboembolic events in patients with cirrhosis?","authors":"Marie M Plante, Emily B Wolf, Razvan M Chirila","doi":"10.3949/ccjm.91a.23045","DOIUrl":"10.3949/ccjm.91a.23045","url":null,"abstract":"","PeriodicalId":10245,"journal":{"name":"Cleveland Clinic Journal of Medicine","volume":"91 2","pages":"86-88"},"PeriodicalIF":6.1,"publicationDate":"2024-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139671397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2023 Update in ambulatory general internal medicine. 2023 年门诊普通内科最新进展。
IF 6.1 4区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-01-02 DOI: 10.3949/ccjm.91a.23056
Jason T Alexander, Simran K Singh, Sachin D Shah, Brianna Lambert, Jeremy P Smith

The practice of outpatient medicine is demanding, encompasses a wide scope of practice, and leaves little time for internists to stay up to date with the current literature. This article reviews 5 studies published in 2022 and 2023 that have the potential to change the practice of outpatient medicine. Topics covered include chronic kidney disease, secondary cardiovascular disease, kidney stones, obesity, and lipid management.

门诊医疗工作要求高、范围广,内科医生几乎没有时间了解最新文献。本文回顾了 2022 年和 2023 年发表的 5 篇有可能改变门诊医学实践的研究。涉及的主题包括慢性肾病、继发性心血管疾病、肾结石、肥胖症和血脂管理。
{"title":"2023 Update in ambulatory general internal medicine.","authors":"Jason T Alexander, Simran K Singh, Sachin D Shah, Brianna Lambert, Jeremy P Smith","doi":"10.3949/ccjm.91a.23056","DOIUrl":"10.3949/ccjm.91a.23056","url":null,"abstract":"<p><p>The practice of outpatient medicine is demanding, encompasses a wide scope of practice, and leaves little time for internists to stay up to date with the current literature. This article reviews 5 studies published in 2022 and 2023 that have the potential to change the practice of outpatient medicine. Topics covered include chronic kidney disease, secondary cardiovascular disease, kidney stones, obesity, and lipid management.</p>","PeriodicalId":10245,"journal":{"name":"Cleveland Clinic Journal of Medicine","volume":"91 1","pages":"40-46"},"PeriodicalIF":6.1,"publicationDate":"2024-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139086019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gastric intestinal metaplasia and gastric cancer prevention: Watchful waiting. 胃肠化生与胃癌预防:谨慎等待
IF 6.1 4区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-01-02 DOI: 10.3949/ccjm.91a.23015
Shrouq Khazaaleh, Mohammad Alomari, Mamoon Ur Rashid, Daniel Castaneda, Fernando J Castro

Gastric intestinal metaplasia (GIM), a common histologic finding, is associated with increased risk of gastric cancer, and GIM associated with Helicobacter pylori infection is classified as an environmental metaplastic atrophic gastritis. Patients may be asymptomatic or present with various dyspeptic symptoms. Autoimmune metaplastic atrophic gastritis is a less common but important cause of chronic gastritis. The Correa cascade describes the evolution of precancerous mucosal changes that lead to development of GIM, with differentiation of 2 histologic types of GIM (complete and incomplete) and the consequences of each type. The risk of progression to malignancy is higher with incomplete GIM. It is also higher for those who immigrate from regions with a high incidence of H pylori infection to areas where the incidence is low. Guidelines regarding endoscopic management of GIM vary by geographic region.

胃肠化生(GIM)是一种常见的组织学发现,与胃癌风险的增加有关,与幽门螺杆菌感染相关的胃肠化生被归类为环境性变性萎缩性胃炎。患者可能没有症状,也可能出现各种消化不良症状。自身免疫性变性萎缩性胃炎是慢性胃炎中较少见但重要的病因。科雷亚级联描述了导致 GIM 的癌前粘膜病变的演变过程,并区分了 GIM 的两种组织学类型(完全性和不完全性)以及每种类型的后果。不完全 GIM 发展为恶性肿瘤的风险更高。从幽门螺杆菌感染率高的地区移民到感染率低的地区的风险也更高。GIM 的内镜治疗指南因地理区域而异。
{"title":"Gastric intestinal metaplasia and gastric cancer prevention: Watchful waiting.","authors":"Shrouq Khazaaleh, Mohammad Alomari, Mamoon Ur Rashid, Daniel Castaneda, Fernando J Castro","doi":"10.3949/ccjm.91a.23015","DOIUrl":"10.3949/ccjm.91a.23015","url":null,"abstract":"<p><p>Gastric intestinal metaplasia (GIM), a common histologic finding, is associated with increased risk of gastric cancer, and GIM associated with <i>Helicobacter pylori</i> infection is classified as an environmental metaplastic atrophic gastritis. Patients may be asymptomatic or present with various dyspeptic symptoms. Autoimmune metaplastic atrophic gastritis is a less common but important cause of chronic gastritis. The Correa cascade describes the evolution of precancerous mucosal changes that lead to development of GIM, with differentiation of 2 histologic types of GIM (complete and incomplete) and the consequences of each type. The risk of progression to malignancy is higher with incomplete GIM. It is also higher for those who immigrate from regions with a high incidence of <i>H pylori</i> infection to areas where the incidence is low. Guidelines regarding endoscopic management of GIM vary by geographic region.</p>","PeriodicalId":10245,"journal":{"name":"Cleveland Clinic Journal of Medicine","volume":"91 1","pages":"33-39"},"PeriodicalIF":6.1,"publicationDate":"2024-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139086022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nonstatin therapy to reduce low-density lipoprotein cholesterol and improve cardiovascular outcomes. 非司他汀疗法可降低低密度脂蛋白胆固醇,改善心血管预后。
IF 6.1 4区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-01-02 DOI: 10.3949/ccjm.91a.23058
Abhayjit Singh, Leslie S Cho

Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality, with low-density lipoprotein (LDL) cholesterol being a causative risk factor. Though statins have a decades-long track record of efficacy and safety, nonstatin agents may be used to reduce LDL cholesterol as an adjunct or alternative to statin therapy. Several new nonstatin medications have been approved in recent years, with robust data from clinical trials supporting their use in atherosclerotic disease. This review addresses the indications, evidence, and important prescribing considerations for using nonstatin lipid-lowering therapy and proposes a practical approach for determining when to initiate nonstatin therapy.

动脉粥样硬化性心血管疾病(ASCVD)是发病率和死亡率的主要原因,而低密度脂蛋白(LDL)胆固醇是一个致病风险因素。虽然他汀类药物的疗效和安全性已有几十年的历史,但非他汀类药物也可用于降低低密度脂蛋白胆固醇,作为他汀类药物治疗的辅助或替代药物。近年来,几种新的非他汀类药物已获得批准,临床试验的可靠数据支持其在动脉粥样硬化疾病中的应用。本综述探讨了使用非他汀类降脂药物的适应症、证据和重要的处方注意事项,并提出了一种实用的方法来确定何时开始使用非他汀类药物治疗。
{"title":"Nonstatin therapy to reduce low-density lipoprotein cholesterol and improve cardiovascular outcomes.","authors":"Abhayjit Singh, Leslie S Cho","doi":"10.3949/ccjm.91a.23058","DOIUrl":"10.3949/ccjm.91a.23058","url":null,"abstract":"<p><p>Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality, with low-density lipoprotein (LDL) cholesterol being a causative risk factor. Though statins have a decades-long track record of efficacy and safety, nonstatin agents may be used to reduce LDL cholesterol as an adjunct or alternative to statin therapy. Several new nonstatin medications have been approved in recent years, with robust data from clinical trials supporting their use in atherosclerotic disease. This review addresses the indications, evidence, and important prescribing considerations for using nonstatin lipid-lowering therapy and proposes a practical approach for determining when to initiate nonstatin therapy.</p>","PeriodicalId":10245,"journal":{"name":"Cleveland Clinic Journal of Medicine","volume":"91 1","pages":"53-63"},"PeriodicalIF":6.1,"publicationDate":"2024-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139086025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cleveland Clinic Journal of Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1